Ghent University Academic Bibliography

Advanced

Current status and progress of prepandemic and pandemic influenza vaccine development

Isabel Leroux-Roels UGent and Geert Leroux-Roels UGent (2009) EXPERT REVIEW OF VACCINES. 8(4). p.401-423
abstract
H5N1 viruses are widely considered to be a probable cause of the next influenza pandemic Influenza vaccines are considered to form the main prophylactic measure against pandemic influenza. The world's population is expected to have no pre-existing immunity against the pandemic virus strain and will need two vaccine doses to acquire protective immunity. A pandemic outbreak will spread much faster than it will take for pandemic vaccines to be produced and distributed. Therefore, increasing efforts are being made to develop prepandemic vaccines that can induce broad cross-protective responses and that can be administered as soon as a pandemic is declared or even before, in order to successfully prime the immune system and allow for a rapid and protective antibody response with one dose of the pandemic vaccine. Several vaccine manufacturers have developed candidate pandemic and prepandemic vaccines, predominantly based on reverse-genetics reference strains and have improved the immunogenicity by formulating these vaccines with different adjuvants. Clinical studies with inactivated split-virion or whole-virion vaccines based on H5N1 indicate that two immunizations appear necessary to elicit the level of immunity required to meet licensure criteria. A detailed overview is given of the most successful candidate vaccines developed by seven vaccine manufacturers.
Please use this url to cite or link to this publication:
author
organization
year
type
journalArticle (review)
publication status
published
subject
keyword
adjuvant, SPLIT-VIRION, cross-neutralization, dose sparing, H5N1, influenza, pandemic, prepandemic, preparedness plan, vaccine, A H5N1 VACCINE, A/DUCK/SINGAPORE/97 VACCINE, RANDOMIZED CONTROLLED-TRIAL, CROSS-REACTIVE IMMUNITY, VIRUS H5N1, MF59-ADJUVANTED INFLUENZA, HEALTHY-ADULTS, CELL-CULTURE, PHASE-I
journal title
EXPERT REVIEW OF VACCINES
Expert Rev. Vaccines
volume
8
issue
4
pages
401 - 423
Web of Science type
Review
Web of Science id
000265860900010
JCR category
IMMUNOLOGY
JCR impact factor
4.214 (2009)
JCR rank
25/126 (2009)
JCR quartile
1 (2009)
ISSN
1476-0584
DOI
10.1586/ERV.09.15
language
English
UGent publication?
yes
classification
A1
id
2127555
handle
http://hdl.handle.net/1854/LU-2127555
date created
2012-05-31 22:21:47
date last changed
2016-12-19 15:42:56
@article{2127555,
  abstract     = {H5N1 viruses are widely considered to be a probable cause of the next influenza pandemic Influenza vaccines are considered to form the main prophylactic measure against pandemic influenza. The world's population is expected to have no pre-existing immunity against the pandemic virus strain and will need two vaccine doses to acquire protective immunity. A pandemic outbreak will spread much faster than it will take for pandemic vaccines to be produced and distributed. Therefore, increasing efforts are being made to develop prepandemic vaccines that can induce broad cross-protective responses and that can be administered as soon as a pandemic is declared or even before, in order to successfully prime the immune system and allow for a rapid and protective antibody response with one dose of the pandemic vaccine. Several vaccine manufacturers have developed candidate pandemic and prepandemic vaccines, predominantly based on reverse-genetics reference strains and have improved the immunogenicity by formulating these vaccines with different adjuvants. Clinical studies with inactivated split-virion or whole-virion vaccines based on H5N1 indicate that two immunizations appear necessary to elicit the level of immunity required to meet licensure criteria. A detailed overview is given of the most successful candidate vaccines developed by seven vaccine manufacturers.},
  author       = {Leroux-Roels, Isabel and Leroux-Roels, Geert},
  issn         = {1476-0584},
  journal      = {EXPERT REVIEW OF VACCINES},
  keyword      = {adjuvant,SPLIT-VIRION,cross-neutralization,dose sparing,H5N1,influenza,pandemic,prepandemic,preparedness plan,vaccine,A H5N1 VACCINE,A/DUCK/SINGAPORE/97 VACCINE,RANDOMIZED CONTROLLED-TRIAL,CROSS-REACTIVE IMMUNITY,VIRUS H5N1,MF59-ADJUVANTED INFLUENZA,HEALTHY-ADULTS,CELL-CULTURE,PHASE-I},
  language     = {eng},
  number       = {4},
  pages        = {401--423},
  title        = {Current status and progress of prepandemic and pandemic influenza vaccine development},
  url          = {http://dx.doi.org/10.1586/ERV.09.15},
  volume       = {8},
  year         = {2009},
}

Chicago
Leroux-Roels, Isabel, and Geert Leroux-Roels. 2009. “Current Status and Progress of Prepandemic and Pandemic Influenza Vaccine Development.” Expert Review of Vaccines 8 (4): 401–423.
APA
Leroux-Roels, I., & Leroux-Roels, G. (2009). Current status and progress of prepandemic and pandemic influenza vaccine development. EXPERT REVIEW OF VACCINES, 8(4), 401–423.
Vancouver
1.
Leroux-Roels I, Leroux-Roels G. Current status and progress of prepandemic and pandemic influenza vaccine development. EXPERT REVIEW OF VACCINES. 2009;8(4):401–23.
MLA
Leroux-Roels, Isabel, and Geert Leroux-Roels. “Current Status and Progress of Prepandemic and Pandemic Influenza Vaccine Development.” EXPERT REVIEW OF VACCINES 8.4 (2009): 401–423. Print.